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Abstract  30 
 31 
While direct to consumer health-related genetic testing (DTCGT) has potential to 32 
provide accessible genetic information and empower individuals to make informed 33 
healthcare decisions, it attracts concern associated with regulatory gaps, clinical utility 34 
and potential for harm. Understanding public reactions to DTCGT is vital to facilitate 35 
considered regulatory, health care and consumer protection strategies. Yet little is 36 
known, particularly outside the dominant US market, about how the general public view 37 
and might engage with health-related genetic testing outside traditional health care 38 
systems. This paper addresses this knowledge gap with the first empirical study to 39 
investigate general public views across four countries, at different stages of market 40 
development. US (n = 1000), UK (n = 1014), Japanese (n = 1018) and Australian (n = 41 
1000) respondents completed an online experimental survey assessing numerous 42 
variables including comprehension, risk perceptions and potential psychological and 43 
behavioural outcomes by type of test (disease pre-disposition and drug sensitivity), 44 
severity, lifestyle factors and family history. Results showed low awareness and 45 
intention to purchase across countries, highest in the US and lowest in Japan. Results 46 
also showed clear preference for within-country purchases (less in Japan), while 47 
purchasing via a doctor was far more important in Japan. Across countries, respondents 48 
were more likely to act on test results where there was a higher genetic or lifestyle risk 49 
of developing a disease. Statistical comparisons of demographic and health-related 50 
variables across countries point to the need for further analyses designed to explain  51 
cross-cultural, cross-health care system and developed versus developing market 52 
differences.  53 
Key Words: Direct to consumer genetic test, cross cultural research, public opinion  54 
3 
Introduction 55 
From the outset, commercial DNA testing has been controversial, with the first entrants 56 
criticized for ‘selling the imprimatur of science’, invoking ‘science’s power without 57 
accepting its limits’ and failing to make clear ‘the limitations and potential dangers’ [1]. 58 
Since DTCGT company 23andMe invited Americans to its first online ‘spit party’ in 59 
2007,[2] the controversy has intensified, with direct-to-consumer health-related genetic 60 
testing (DTCGT) deemed ‘one of the most promising, yet controversial medical 61 
advances of the modern era’[3] and viewed as a major aspect of the age of personalised 62 
medicine[4]. Yet DTCGT has potential as ‘a powerful mechanism for providing 63 
comprehensive genomic information to a large number of individuals’[3], capable of 64 
fostering consumer empowerment [5] relative to healthcare and lifestyle decision-65 
making [6], without further diminishing limited public healthcare resources. Industry 66 
advocates argue DTCGT enables ‘individuals to learn about the basics of genetics 67 
through the lens of their own data' with affordable and easily accessible test results 68 
serving as a ‘foundation to preventive care’ [7].  69 
Developments in DTCGT attracted early attention from academics and medical 70 
researchers, [8,9,10] media [11] and those concerned with regulation [12,13,14]. While 71 
recognising DTCGT’s potential to empower consumers, the majority emphasised 72 
ethical, legal and social issues associated with obtaining genetic information outside 73 
healthcare systems. Concern has been expressed about DTCGT tests, questioning 74 
accuracy (analytic validity), link to increased disease risk (clinical validity) and whether 75 
treatment options or lifestyle changes exist to mitigate or at least manage indicated risk 76 
(clinical utility) [15,16]. 77 
One key issue with DTCGT has been, and continues to be, the potential for 78 
consumer harm, especially if consumers use test results to make significant independent 79 
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treatment, prevention and lifestyle decisions [17]. Disease pre-disposition tests do not 80 
generate definitive results but rather probabilities, creating the potential for ‘unjustified 81 
anxiety’ from false positive test results and ‘false reassurance’ from false negative 82 
results. Consumers self-interpret results, as advice from trained professionals is 83 
generally not a standard component of the DTCGT offering [18]. Even if tests are 84 
accurate, consumers generally do not have the required knowledge and skills to interpret 85 
and appropriately action test results, and may turn to the healthcare system for 86 
assistance [19], shifting the burden back onto public resources [20].  87 
Understanding public reaction to DTCGT is vital to inform considered regulatory, 88 
healthcare and consumer protection strategies. Research with the general public is still 89 
in its infancy, consisting mainly of unintegrated descriptive studies examining wide-90 
ranging topics (e.g. awareness, attitudes, interest, intentions) across an assortment of 91 
samples, primarily US (students, general public, early DTCGT customers). With rising 92 
access to global markets and increased promotion, especially online, it is imperative to 93 
understand developed, developing and potential markets to assess DTCGT’s potential 94 
risks and benefits and whether these vary depending on regulatory regimes, healthcare 95 
systems and cultural views. Importantly, there is no publicly available cross-96 
jurisdictional research comparing drivers and outcomes such as results comprehension, 97 
psychological and behavioural reactions, likelihood of seeking professional healthcare 98 
involvement, and willingness to allow company use of submitted DNA.  There is also 99 
no cross-jurisdictional research directly comparing purchase and purchase intention 100 
within or outside one’s country of residence.  101 
This study is the first to directly compare public engagement with DTCGT across 102 
the more developed market in the US, where the majority of DTCGT companies are 103 
located (n = 1000), with two relatively newer markets in Australia (n = 1000) and the 104 
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United Kingdom (n = 1014) and the emerging Japanese market (n = 1018). The study 105 
was designed to be cross-sectional, bringing together numerous, often interrelated 106 
variables that may influence past and future DTCGT purchase. The core of the survey 107 
was the experimental component designed to assess comprehension and psychological 108 
and behavioural reactions to hypothetical DTCGT reports that varied according to the 109 
type of test (type 2 diabetes, colorectal cancer, drug sensitivity), severity of risk, 110 
lifestyle/family history information and validity of genetic results. The survey also 111 
included a range of demographic and health-related variables and predictive factors, 112 
such as DTCGT familiarity, genetic determinism beliefs, trust in health information 113 
sources, privacy concerns, numeric ability and existing health-related behaviour.  114 
The study thereby facilitated advanced analyses and nuanced insights relative to 115 
measures needed to ensure regulatory and healthcare responses to DTCGT appropriately 116 
reflect public concerns and values. Given the study's breadth and complexity, this 117 
paper's purpose is to present its design and measures together with the sample 118 
characteristics from each countries. We also provide cross country results associated 119 
with awareness of DTCGT, willingness to purchase, and whether decisions would be 120 
made based on receiving different results that varied across type of disease and severity. 121 
We expected that US respondents would be more aware and would demonstrate higher 122 
willingness to purchase a test, given the dominance of the US market. However other 123 
differences were exploratory given the limited research in Australia, the UK and 124 
especially Japan, where there is currently none. Further work is being undertaken to 125 
analyse more fully the reasons for country differences to inform effective consumer 126 
protection and community engagement. 127 
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Materials and Methods 128 
The research design was driven by four main questions: 1) Is there potential for 129 
consumer harm, in particular psychological, resulting from engagement with DTCGT? 130 
2) Do DTCGT results motivate behavioural change? 3) What determines familiarity 131 
with and intention to purchase DTCGT? and 4) Do responses vary by country, type of 132 
test, and respondent? An online survey of US, Australian, Japanese and UK respondents 133 
was designed to assess the study’s aims. Respondents were sourced by Qualtrics and 134 
administered in Australia and the US in March 2015, the UK in September 2015 and 135 
Japan in December 2015. Qualtrics provided stringent quality control features such as 136 
the ability to screen for dishonest, inaccurate and speedy respondents, use of 137 
sophisticated digital fingerprinting to avoid duplication, and compliance with ISO 138 
standard and industry standard data protection and security procedures. Quotas ensured 139 
country samples were roughly gender and age representative of target populations: 51% 140 
female, 49% male; with 48% younger (18 - 24 + 25 - 44 years) and 52% older (45 - 64 141 
and 65+ years).  142 
The experimental component was designed to assess comprehension and potential 143 
for psychological detriment and behavioural change, focusing specifically on disease 144 
pre-disposition and drug sensitivity (pharmacogenomics). Each respondent was 145 
presented with three scenarios involving DTCGT results for named individuals relating 146 
to type 2 diabetes, colorectal cancer and sensitivity to a genetic blood-thinning drug. 147 
Respondents were presented population average risk and randomised personal risk for 148 
the two diseases and metabolisation rate for the drug. Respondents first were asked 149 
questions designed to assess understanding, general disease perceptions and risk 150 
interpretation for the diseases and understanding for the drug. Respondents were then 151 
asked to assume they received comparable results to the named individuals and to 152 
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answer questions designed to measure potential psychological consequences and 153 
behavioural intentions in response to results. (see Figure 1 for conceptual representation 154 
of survey design).  155 
All respondents answered questions before and after the experimental component 156 
designed to assess: DTCGT familiarity; purchase and purchase intention; confidence in 157 
DTCGT offering; willingness to participate in company research; trust in health 158 
information sources; health fatalism; beliefs in genetic determinism; health-related 159 
behaviours; and personal health (survey available via authors). All respondents 160 
answered the same questions except for those requiring country-specific adaptation (e.g. 161 
education, income). The survey used for Japan was available in English and Japanese 162 
versions, with translation conducted by professional translators, requiring several 163 
iterations to match meaning and context before final approval. The study obtained 164 
Ethics approval from the University of Tasmania and Osaka University.  165 
Figure 1 Here 166 
Experimental design 167 
The three scenarios reflect the types of reports currently delivered by DTCGT services. 168 
Respondents were allocated gender-specific versions, with male and female names 169 
common in each country used. For the two diseases, respondents were randomly 170 
assigned low, high or higher risk for their named individual representing the population 171 
average risk -20%, +20% and +100% (based on population risk used by US DTCGT 172 
company 23andMe). Scenarios also included known causal factors - lifestyle for 173 
diabetes and family history for colorectal cancer. Respondents were randomly allocated 174 
into scenarios where named individuals either had or did not have causal factors or into 175 
controls with no additional information (9 different treatments per disease – see Table 176 
1).  177 
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Table 1 here 178 
For drug sensitivity, respondents were randomly assigned slow or fast 179 
metabolisation rate for named individuals. Scenarios also included information about 180 
whether tests were based on small or large numbers of scientific studies (preliminary vs. 181 
established research as used by 23andMe) and whether studies suggested no negative 182 
effects from either increasing or decreasing dosage. Respondents were randomly 183 
assigned research and negative effect information or received only metabolisation rate, 184 
(10 different treatments; See Table 1). Respondents received one treatment each for 185 
diabetes, cancer and drug sensitivity, in that order. Quotas for randomisation into each 186 
of the total 28 treatments generated near equal numbers. (n per treatment: 108 – 116 per 187 
country).  188 
For each of the three scenarios, respondents were first asked to rate their 189 
understanding of results presented. For the two diseases, respondents were asked 190 
whether named individuals could prevent the disease, and then to interpret their 191 
randomised DTCGT results based on the named individual's likelihood of developing 192 
the disease (termed perceived severity) compared to the population average (termed 193 
actual severity). Respondents were then asked to assume they received the same results 194 
as named individuals and to assess their personal perceived risk of developing the 195 
disease; potential psychological distress (ten randomly presented affect states adapted 196 
from the Positive and Negative Affect Scale) [21]; and a range of randomly presented 197 
behavioural intentions including lifestyle changes (e.g. diet); sharing (e.g. family or 198 
online), engagement with healthcare professionals (e.g. doctors for interpretation); 199 
information-seeking (e.g. online) or intention to make no decisions. 200 
For drug sensitivity, respondents were also asked to assume they received the same 201 
results as named individuals and whether they would make decisions based on results. 202 
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They then assessed potential psychological distress (same affect states as above); and 203 
indicated whether they would alter their medication regime independently or only after 204 
expert advice.  205 
Introductory and post experimental responses 206 
For quota purposes, respondents were asked at the outset to indicate gender, age and 207 
state of residence (based on country of residence). They were presented with a brief 208 
description of DTCG to ensure sufficient knowledge to complete the survey. Questions 209 
were then asked about pre-survey DTCGT familiarity and intention to purchase tests 210 
from either onshore or offshore companies. After the experimental component, all 211 
respondents assessed their confidence relative to DTCGT (test accuracy, completeness 212 
of information; personal ability to interpret results and sharing only with permission) 213 
and willingness for their data to be used in company research (freely shared with 214 
university researchers; used in company's own research, or sold for profit). Respondents 215 
were asked whether they had purchased tests for either themselves or others and 216 
likelihood of purchase if DNA was provided to companies but results returned via 217 
doctors.  218 
A suite of eighteen questions was asked relating to health consciousness (health 219 
concerns are integrated into daily activities)
 
[22]; health fatalism beliefs (lack of 220 
personal control over health and illness) [23]; genetic determinism (belief genetics 221 
causes illness); and the influence of lifestyle and family history on diabetes and 222 
colorectal cancer development. Six questions were asked to assess recent health-seeking 223 
and sharing behaviours (e.g. online self-diagnosis and sharing in online communities) 224 
and five questions concerning trust in health information sources (e.g. family and 225 
doctors). Two questions tested health numeracy, one testing risk interpretation and one 226 
dosage determination. 227 
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Health and demographic background characteristics 228 
Self-reported health was measured with five questions designed to assess overall health, 229 
diet, exercise, family history of the two diseases and whether respondents took 230 
prescription medication. The survey ended with basic demographic questions: marital 231 
status; education; ethnicity; work status; household income; and number of children 232 
under 18 in household and its total size.   233 
Participants 234 
Descriptive statistics of all demographic variables across country are shown in Tables 1 235 
and 2. The mean age was similar across countries due to quotas but there were wide 236 
levels of variation (i.e., SD’s were around 16 years – see Table 2). Overall the sample 237 
was fairly representative in terms of age, though all countries were slightly under-238 
represented by older respondents, particularly Japan [24, 25]. The samples were also 239 
representative of those with tertiary qualifications, with the proportion being slightly 240 
higher in Japan. The Japanese sample was slightly overrepresented by those with a 241 
tertiary education (i.e. 56.7% compared to 49.5% in the population) [26].  242 
The sample was not representative of those in paid employment, according to 243 
OECD employment rates for 2015 [27]. In 2015, the proportion of Australians between 244 
15 and 65 years in paid employment was 73.6% (sample: 48.9%), US 70.6% (sample: 245 
52.8%), UK 74% (sample: 54.3%) and Japan 76.7% (sample: 59.5%). Interestingly 246 
household income was reasonably representative for the Japanese sample, but slightly 247 
over represented by those on lower incomes in the US, UK and Australia. The median 248 
household income category for Australians was $50K – $74K compared to median 249 
population gross household income of $84,032 in 2015 [28]; for the US $50K - $74K 250 
compared to population median of $57,230 [29]; the UK £23-34,999 compared to 251 
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population median of £25,700 [30]; and Japan ¥5,000,001 – ¥6,000,000 compared to 252 
population median of ¥5,743,488 in 2015 [31]. 253 
Cross-country comparisons of demographic variables (and their intercorrelations) 254 
were conducted to check the validity of the samples and to provide future insight into 255 
possible reasons for why views of DTCGT might vary on a country-specific basis. The 256 
results in Table S1 and Figure S1 (see Supplementary materials) reveal many 257 
demographic differences across countries. Not surprisingly there were no age or gender 258 
differences as quotas were imposed. Overall US and Japanese citizens appeared to be 259 
the most distinct, while Australia and the UK were more similar. Compared to the 260 
Western countries, the Japanese sample had higher education, less children (though 261 
slightly higher household size) and were more likely to be in paid employment and in a 262 
relationship. Japanese respondents were also less likely to use the Internet, report poorer 263 
health and diet, exercise less and report a higher incidence of cancer within their 264 
families. Interestingly however, they were less likely than all other countries to be on 265 
prescription medication and to have a history of diabetes.  266 
US respondents were similar to the other Western cultures in relation to their 267 
demographic background, although they did have the highest number of children living 268 
in their households. They were, however, distinctive from all other countries in terms of 269 
their increased online activity and health status. While reporting the highest levels of 270 
good health and the healthiest diet, they were more likely to be taking prescription 271 
medication and to have a family history of both diabetes and cancer. The UK and 272 
Australia appeared to be most similar, with relatively few significant differences 273 
between them. However, Australians were slightly less likely to be in paid employment, 274 
and reported lower online activity, slightly better health status, healthier diets, and 275 
increased exercised than UK respondents. US respondents were also significantly 276 
12 
(p<.001) more likely to have already purchased a DTCGT either for themselves or 277 
someone else (21.3%) than all other countries who were similar (Australia: 9.5%; UK: 278 
9.3%; Japan: 8.3%). 279 
Tables 1 and 2 Here 280 
Results 281 
Figure 2 shows that all countries displayed low familiarity with DTCGTs. Apart from 282 
the US, the UK, Australia and particularly Japanese respondents’ average familiarity 283 
score was below 2. The US average was above 2 indicating a slight familiarity on 284 
average. Using SPSS V25, a one-way ANOVA with familiarity as the dependent 285 
variable and country as the independent variable revealed significant variation in levels 286 
of familiarity across country (at p<.001). Post hoc comparisons revealed that all 287 
countries’ mean familiarity levels differed significantly from each other (at p<.001). US 288 
respondents showing the highest level of familiarity, followed by UK, Australian and 289 
then Japanese respondents (see Figure 2).  290 
Figure 2 here 291 
As the means for Country TOTAL in Figure 2 show, overall, respondents from all 292 
four countries demonstrated a low intention to purchase a DTCGT. A four (country) by 293 
three (source of test: inside country, outside country, via doctor) mixed design ANOVA 294 
was conducted to explore the differences across country and source in intention to 295 
purchase. The results revealed that the main effect of country was significant (at 296 
p<.001). Thus averaged over all three sources, intention was highest for US, followed 297 
by Australian, UK and Japanese respondents (displayed in Figure 2 as Country 298 
TOTAL). All post hoc comparisons were significant, suggesting that overall intention 299 
was significantly different across all countries. While Australia was found to have a 300 
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significantly higher overall intention score to the UK, this difference was weaker than 301 
all other comparisons (p= .035) which were significant at p<.001. 302 
Comparisons of intention across the three sources of DTCGT were also significant. 303 
Averaged across country (see Source TOTAL in Figure 2), overall intention to purchase 304 
a DTCGT was highest when the purchased test is returned to a doctor, followed by 305 
purchasing from a company inside one’s own country, which was significantly higher 306 
than intention to purchase outside one’s country of residence (all comparisons were 307 
significant at p<.001). The interaction was also significant, suggesting that the 308 
difference across the three sources varied across the four countries. To explore the 309 
nature of the interaction, discrete ANOVA’s were computed to investigate differences 310 
across sources within each country separately. The results suggested that the increased 311 
tendency to purchase when the results are returned to a doctor compared to a company 312 
(inside one’s country) was exacerbated for Japan. For the US, UK and particularly 313 
Australia, the difference in intention was greater between inside and outside of their 314 
countries. Thus the results suggest that the western countries and especially Australia, 315 
are more concerned than the Japanese about tests originating from overseas companies 316 
(see Figure S2 in Supplementary materials for more detail). 317 
Decisions 318 
To explore whether respondents would act on the results presented to them we 319 
compared the likelihood that no decisions would be made on the test results across 320 
countries and scenarios (i.e., If you took a direct-to-consumer genetic test for Type 2 321 
diabetes/colorectal cancer and your test results were the same as Jennifer’s, how likely 322 
is it that you would not make any decisions based on the test results). The diabetes 323 
scenario results of a 4 (Country) by 3 (Risk: Low, High, Higher) by 3 (Causal factors: 324 
Healthy diet, Unhealthy diet, Control) ANOVA revealed significant (all at p<.001) main 325 
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effects for country, risk and causal factors, but no significant interactions. Only 326 
significant main effects (all at p<.001) were also found for the colorectal cancer 327 
scenarios via a 4 (Country) x 3 (Risk: Low, High, Higher) by 3 (Causal factors: Family 328 
history, No family history, Control) ANOVA.  329 
Post hoc comparisons for risk revealed all were significant (at p<.001) for the 330 
diabetes and colorectal cancer scenarios. Respondents were significantly more likely to 331 
report that they would make no decisions when the risk was low (Diabetes: M = 2.99, 332 
SE = .03; Cancer: M=3.18; SE = .03), than when the risk was high (Diabetes: M = 2.84, 333 
SE = .03; Cancer: M = 2.99, SE = .03) and higher (Diabetes: M = 2.63, SE = .03; 334 
Cancer: M = 2.79, SE = .03). Comparisons across causal factors for diabetes found that 335 
no decisions were most likely to occur in response to a healthy lifestyle (M=2.92, SE = 336 
.03) or when no information was provided (M = 2.84, SE = .03) compared to an 337 
unhealthy lifestyle (M = 2.70, SE = .03). A similar pattern was found for the cancer 338 
scenario where no decisions were more likely in response to no family history (M=3.03, 339 
SE = .03) or no information (M=3.04, SE = .03) compared to when the target person 340 
was described as having a family history of cancer (M=2.89, SE = .03). Post hoc 341 
comparisons across countries for both scenarios revealed the only significant difference 342 
was between US and Australian respondents. As shown in Figure 3 US respondents 343 
were more likely to make no decisions based on either the diabetes or cancer scenarios 344 
than Australians.  345 
Figure 3 here 346 
For the drug sensitivity scenario, two separate ANOVA’s were computed as the 347 
control groups for validity and dose information were not independent (see Table 1). 348 
The first consisted of a 4 (country) x 2 (Report results: Slow, Fast metaboliser) x 3 349 
(Validity: Preliminary, Established, Control) design, and the second a 4 (country) x 2 350 
15 
(Report results) x 3 (Dose: Increase, Decrease, Control). Apart from a significant (at 351 
p<.001) main effect for country, the first ANOVA yielded no significant effects. The 352 
second however revealed significant main effects for country (p<.001) and dose 353 
(p=.009), as well as a significant country x dose interaction, F(6, 4008) = 2.38, p = .028, 354 
η
2
 = .004). Post hoc comparisons for country revealed that US respondents were more 355 
likely to make no decisions in response to the drug sensitivity scenario compared to all 356 
other countries (all at p<.001) whom were statistically similar (see Figure 3).  357 
To explore the significant interaction, separate ANOVA’s for each country were 358 
computed across dose information. Significant differences were found only for US 359 
respondents, where no decisions were more likely (at p<.001) when the evidence given 360 
for reduced negative effects of changing medication was associated with increasing the 361 
dose compared to decreasing it and providing no evidence (i.e., control condition) (See 362 
Figure 4).  363 
Figure 4 here 364 
Discussion 365 
Regulating in areas of emerging or rapidly developing technologies, with evolving 366 
industry structures, presents particular challenges [4, 37]. As a general principle, 367 
regulation should be ethically and legitimately appropriate, reflect consensus opinion 368 
accommodating differing belief systems to ensure regulatee acceptance, while being 369 
responsive to technological developments (future-proofed) [38]. A recurring theme in 370 
the DTCGT literature is that ethical, legal and social issues involved are sufficiently 371 
serious to require regulation [33,34,35,36].  As the majority of activity and development 372 
in the DTCGT sector is centred in the US but available online, resulting jurisdictional 373 
challenges require consideration at an international level [39]. An understanding of 374 
public opinion across different countries on the range of issues is crucial to inform 375 
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development of appropriate national and international regulatory frameworks. This 376 
project provides a foundation for future comparative analyses associated with DTCGT 377 
in newer markets, with different cultural perspectives and healthcare systems to those in 378 
the more established US market. 379 
As expected, our findings suggest that awareness of DTCGT and intention to 380 
purchase a test were substantially higher in the established US market than the newer 381 
markets of the UK, Australia and especially Japan. Suggesting that within jurisdiction 382 
regulatory approaches are a priority, respondents from all countries (including the US) 383 
reported being more likely to purchase a test from a company within their own country 384 
and even more likely if it was purchased via a doctor. However our results also suggest 385 
that intention to purchase a test from an international company is likely to grow with 386 
increasing awareness, thereby requiring harmonisation at the international level. This is 387 
particularly the case in countries like Japan where awareness was very low and the 388 
effect of a company’s location on respondents’ intention was less pronounced. 389 
Moreover, preliminary results from the experimental component of our study suggest 390 
strongly that respondents are more likely to make decisions to act on test results (rather 391 
than doing nothing) if genetic results or lifestyle factors communicate higher predictive 392 
risk for developing a disease.  393 
The logical next step in this study is to determine the potential for harm or benefit, 394 
by establishing the nature of, and the reasons behind, decisions taken in response to 395 
different scenarios in different countries. The reasons for the differences found in this 396 
research need to be examined, especially the intriguing result that US respondents were 397 
less likely to make active decisions based on test results than Australians, especially if 398 
they received further information relating to the validity of a test. Analysis of the 399 
demographic variables across the four countries reveals significant potential to generate 400 
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valuable future insights into the reasons underlying potential reactions as well as cross-401 
cultural differences. Indicating potential for generalisability, the samples are relatively 402 
representative of the US, UK, Australian and Japanese populations, and sufficiently 403 
heterogenous to allow within-country comparisons. All were representative in relation 404 
to gender and education, and reasonably representative in terms of age, with the 405 
exception of Japan, which was slightly over represented by younger respondents.  406 
Providing confidence in the generalisability of the samples, many of the identified 407 
demographic differences reflected actual differences in the populations. For example, 408 
the higher rates of respondents with university/college educations and those in 409 
employment amongst the Japanese population compared to the three other countries was 410 
reflected in the sample differences [26, 27]. The higher incidence of type 2 diabetes in 411 
the US (10.8%) compared to the other three countries (Australia: 5.2%, UK: 4.3%, 412 
Japan: 5.7%) [40], higher rates of colorectal cancer in Japan and the US compared to 413 
Australia and the UK [41], and higher use of prescription medication amongst US 414 
respondents [42] were also reflected in the pattern of results. 415 
The four sample jurisdictions were, however, over-represented by those not in paid 416 
employment and, with the exception of the Japanese sample, those with lower 417 
household incomes. This may reflect the nature of the online panel respondents, who are 418 
active Internet users [43] and may be more motivated by small incentives (e.g. reward 419 
points). However, this study required Internet-literate respondents, confirmed by 420 
respondents’ relatively high Internet usage (especially US). While these factors may 421 
present limitations, more recent research suggests demographic differences between 422 
online panel respondents and those recruited by other methods (e.g. telephone) may be 423 
diminishing with increased household Internet penetration [44], and companies 424 
(including Qualtrics) partnering with other panel providers to allow access to larger, 425 
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more diverse or targeted populations. Sample diversity and representativeness in 426 
relation to key variables such as gender, age and education in this study are indicative of 427 
improvements in online recruitment practices.  428 
There is now an emerging body of empirical studies of consumer interactions with 429 
DTCGT [45,46,47,48], yet few commentators have made recommendations on 430 
regulatory or oversight requirements, particularly in relation to cross-jurisdictional 431 
challenges [49,50]. The results of this four-country cross-jurisdictional DTCGT study 432 
provide a basis to inform substantive recommendations in relation to ethical, legal and 433 
social issues, at least in the four countries studied. Finally, this study can provide an 434 
important opportunity and international template to further investigate DTCGT 435 
engagement with respondents in other jurisdictions with differing demographic profiles, 436 
legal and healthcare systems, regulatory regimes, and cultural traditions. 437 
Supplementary information is available at European Journal of Human Genetics’ 438 
website 439 
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Table 1. Description of Report Design 
Diabetes (average risk reported as 20.7% for all)  














lifestyle Control  
Report No. 1 2 3 4 5 6 7 8 9  
           
Colorectal cancer (average risk reported as 4.0% for all)  














history Control  
Report No. 10 11 12 13 14 15 16 17 18  
           
 Drug sensitivity (metabolic rate compared to the average person) 
Report 
results Slow metaboliser Faster metaboliser 
Validity Preliminary research (Small no. of studies) 
Established research 
(Large no. of studies) Control 
Preliminary research 
(Small no. of studies) 
Established research 


















Report No. 19 20 21 22 23 24 25 26 27 28 
Note. All control conditions were those where causal information was omitted for the two disease reports, and where research background and 
effect of dose information were omitted for the Drug sensitivity reports. 
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Table 2. Descriptive Statistics for all categorical demographic variables across country.  
  Total Australia US UK Japan 
  n % n % n % n % n % 
Gender Male 1973 48.9 490 49.0 490 49.0 495 48.8 498 48.9 Female 2059 51.1 510 51.0 510 51.0 519 51.2 520 51.1 
Education 
Not university 
educated 2164 53.7 561 56.1 574 57.4 588 58.0 441 43.3 
University 
educated 1868 46.3 439 43.9 426 42.6 426 42.0 577 56.7 
Employment 
status 
Paid employment 2174 53.9 489 48.9 528 52.8 551 54.3 606 59.5 
Not in paid 
employment 1615 40.1 435 43.5 429 42.9 408 40.2 343 33.7 
Student 243 6.0 76 7.6 43 4.3 55 5.4 69 6.8 
Marital status Not partnered 1760 43.7 407 40.7 420 42.0 425 41.9 508 49.9 Partnered 2272 56.3 593 59.3 580 58.0 589 58.1 510 50.1 
Ethnicitya 
Majority 2843 82.5 567 69.1 648 74.1 855 92.2 773 93.8 
Minority 157 4.6 3 0.40 140 16.0 14 1.5 0 0.0 
Outside country 446 12.9 251 30.6 86 9.8 58 6.3 51 6.2 
Diabetes 
history 
Yes 1106 27.7 260 26.3 384 38.6 256 25.5 206 20.3 
No 2554 63.9 606 61.4 524 52.7 673 67.0 751 74.1 




Yes 355 8.9 72 7.30 121 12.2 56 5.6 106 10.5 
No 3148 78.8 730 74.1 744 74.8 827 82.2 847 83.9 
Unsure 493 12.3 183 18.6 130 13.1 123 12.2 57 5.6 
Prescription 
medication 
No 2124 53.6 496 50.7 430 43.9 504 50.5 694 69.1 
Yes 1836 46.4 483 49.3 549 56.1 494 49.5 310 30.9 
Note. aMajority was defined as those who identified as Australian, American, English/British/Welsh/Scottish or Japanese. For Australia, US and 
UK respondents this also included those indicating “white” or “Caucasian” and “Asian” for Japanese respondents. Minority was defined as 
black, African American, Latino, and indigenous, while the category “Outside country” were those who identified with a culture outside their 
country of residence (e.g., German, Middle Eastern, Chinese). 
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Table 3. Descriptive statistics for all continuous demographic variables across country.  
 TOTAL Sample Australia US UK Japan 
 M SD M SD M SD M SD M SD 
Age 46.51 16.56 47.20 17.11 46.84 17.02 46.18 16.43 45.83 15.65 
Household 
Incomea 
2.54 1.03 2.66 0.97 2.51 1.01 2.50 1.04 2.48 1.10 
Household size 2.69 1.35 2.68 1.38 2.69 1.43 2.61 1.31 2.78 1.28 
No. Children 1.52 0.94 1.54 0.99 1.69 1.10 1.51 0.90 1.33 0.71 
Health status 3.20 0.94 3.23 0.93 3.48 0.98 3.13 0.93 2.94 0.82 
Healthy diet 3.29 0.93 3.37 0.92 3.27 1.00 3.28 0.88 3.22 0.93 
Exercise 2.82 2.30 3.27 2.23 3.11 2.29 2.98 2.21 1.95 2.25 
Online activity 1.92 0.65 1.92 0.62 2.07 0.66 1.99 0.63 1.70 0.63 
 
Note. M = Mean, SD = Standard deviation. aHousehold income for each country was initially 8 categories for all except Japan which was 9. 
To standardardise the currencies 4 income categories were created where 2 SD’s below the country’s mean was defined as low, 1 SD below 
the mean was Low-medium, 1 SD above and including the mean was Medium to high and 2 SD’s above the mean as High. Ranges for the 
other variables were: Age = 18 – 91 years, Household size = 1 – 12, Number of children = 1 – 11 (There were no respondents without 
children living in the household), Health status = 1 (poor) – 5 (very good), Diet = 1(very unhealthy) – 5 (very healthy), Exercise = 0 – 7 days 
per week, Online searching = 1 (never) – 3 (regularly). There were no missing values on all variables apart from household income (prefer 




Figure 2. Mean level of familiarity and intention to purchase across country.  
Note. Bars represent the 95% confidence intervals of the mean. For Familiarity (Prior to 
starting this survey, how familiar were you with direct-to-consumer genetic testing?), 1 = Not 
familiar, 2 = Slightly familiar, 3 = Somewhat familiar, 4 = Moderately familiar and 5 = 
Extremely familiar. For intention (“What would you say is the likelihood of you purchasing a 
direct-to-consumer genetic test from a company located INSIDE/OUTSIDE your country of 
residence?; How likely it would be that you would purchase a direct-to-consumer genetic test 
if you provided your DNA sample to the company but the company returned your test results 
to your doctor?) 1 = Extremely unlikely, 2 = Unlikely, 3 = Neutral, 4 = Likely and 5 = 
Extremely likely. Source TOTAL is the mean intention for each source averaged across 







































Figure 3. Mean decision score across country. 
Note. High scores = Higher likelihood of making no decisions in response the scenario. Bars 




Figure 4. Mean decision score across country and dose information. 
Note. High scores = Higher likelihood of making no decisions in response the scenario. Bars 
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